GOG FOUNDATION®
Transforming the standard of care™

GOG PARTNERS



GUIDE TO ABSTRACTS, POSTERS AND SESSIONS

GYNECOLOGIC ONCOLOGY, CLINICAL TRIALS, IMMUNOTHERAPY

ASCO 2023 | JUNE 1 - 6, 2023 - CHICAGO, IL

2023 ASCO Full Program Guide

CLINICAL SCIENCE SYMPOSIUM: KNIVES OUT: SURGICAL MANAGEMENT OF GYNECOLOGIC CANCERS

Date: June 2, 2023 |2:45 PM CDT | Location: E451

2:45 PM CDT: Knives Out: Surgical Management of Gynecologic Cancers
Discussant: Michael Thomas McHale | University of California, San Diego

2:57 PM CDT: Final survival analysis of the phase III OVHIPEC-1 trial of hyperthermic intraperitoneal chemotherapy in ovarian cancer after ten year follow-up.
Presenter: Lot Aronson, MD | The Netherlands Cancer Institute - Antoni van Leeuwenhoek
Abstract: 5509

3:09 PM CDT: Hyperthermic intraperitoneal chemotherapy in platinum-sensitive relapsed epithelial ovarian cancer: The CHIPOR randomized phase III trial.
Presenter: Jean-Marc Classe, MD, PhD | Institut de Cancérologie Ouest
Abstract: 5510

3:21 PM CDT: The Heat Is On: What Is the Role of HIPEC in Ovarian Cancer Management?
Discussant: Robert P. Edwards, MD | UPMC Magee-Womens Hospital

3:33 PM CDT: An international randomized phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC). A Gynecologic Cancer Intergroup study led by the Canadian Cancer Trials Group (CCTG CX.5-SHAPE).
Presenter: Marie Plante | Division of Gynecologic Oncology, Université Laval, CHU de Quebec
Abstract: LBA5511

3:45 PM CDT: Cut Less? Decreasing Morbidity in Early Cervical Cancer
Discussant: Jose Alejandro Rauh-Hain, MD | University of Texas MD Anderson Cancer Center

3:57 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

EDUCATION SESSION: ANTIBODY-DRUG CONJUGATES: NEW OPPORTUNITIES IN GYNECOLOGIC CANCER

Date: June 2, 2023 |4:30 PM CDT | Location: S100bc

4:30 PM CDT: What's Here and What's on the Horizon
Chair: Bhavana Pothuri, MD, MS | New York University School of Medicine

4:45 PM CDT: Management of Unique Ocular Toxicities
Speaker: Stella K. Kim, MD | University of Texas Medical School at Houston

5:00 PM CDT: What Makes Treatment Worth It
Speaker: Sachia Stonefeld Powell | Patient Advocate

5:15 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

CASE-BASED PANEL: RARE GYNECOLOGIC CANCERS: A CASE OF GESTATIONAL TROPHOBLASTIC NEOPLASIA

Date: June 3, 2023 |1:15 PM CDT | Location: S102

1:15 PM CDT: Moderator
Chair: Martina Cathryn Murphy, MD | University of Florida Health Shands Hospital

Gynecologic Oncology Perspective
Speaker: Kevin Meyer Elias, MD | Brigham and Women's Hospital

Medical Oncology Perspective
Speaker: Benoit You, MD, PhD | Lyon Sud Hospital

Surgical Perspective
Speaker: John T. Soper, MD | University of North Carolina at Chapel Hill

1:55 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

ORAL ABSTRACT SESSION: GYNECOLOGIC CANCER

Date: June 3, 2023 |3:00 PM CDT | Location: S100bc

3:00 PM CDT: KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.
Presenter: Bradley J. Monk, MD | Division of Gynecological Oncology, HonorHealth Research Institute, University of Arizona College of Medicine, Phoenix and Creighton University School of Medicine
Abstract: 5500

GOG PARTNERS

3:12 PM CDT: In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.
Presenter: Isabelle Laure Ray-Coquard, MD, PhD | Centre Léon Bérard, University Claude Bernard Lyon 1
Abstract: 5501

3:24 PM CDT: Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Presenter: Charles A. Leath, MD, MSPH | O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine
Abstract: 5502

3:36 PM CDT: Cervical Cancer: Not Immune to Benefit?
Discussant: Catheryn M. Yashar, MD | UC San Diego Moores Cancer Center

3:48 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

ORAL ABSTRACT SESSION: GYNECOLOGIC CANCER

Date: June 3, 2023 |3:00 PM CDT | Location: S100bc

4:00 PM CDT:Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Presenter: Matthew A. Powell, MD | National Cancer Institute sponsored NRG Oncology, Washington University School of Medicine
Abstract: 5503

GOG PARTNERS

4:12 PM CDT: Patient-reported outcomes (PROs) in primary advanced or recurrent endometrial cancer (pA/rEC) for patients (pts) treated with dostarlimab plus carboplatin/paclitaxel (CP) as compared to CP in the ENGOT-EN6/GOG3031/RUBY trial.
Presenter: Mansoor Raza Mirza, MD | Rigshospitalet, Copenhagen University Hospital, Nordic Society of Gynaecologic Oncology–Clinical Trial Unit
Abstract: 5504

GOG PARTNERS

4:24 PM CDT: Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy: A single-arm phase II trial.
Presenter: Wenjuan Tian, MD, PhD | Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University
Abstract: 5516

4:36 PM CDT: Mining the Landscape of Immunotherapy in Uterine Cancer
Discussant: Gini F. Fleming, MD | University of Chicago Medicine

4:48 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

5:00 PM CDT: Randomized controlled phase III trial of weekly paclitaxel ± ofranergene obadenovec (VB-111) for platinum-resistant ovarian cancer (OVAL Study/GOG 3018).
Presenter: Rebecca Christian Arend, MD | University of Alabama at Birmingham
Abstract: 5505

GOG PARTNERS

5:12 PM CDT: Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial.
Presenter: Philipp Harter, MD, PhD | Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, and AGO
Abstract: LBA5506

5:24 PM CDT: Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.
Presenter: Ana Oaknin, MD, PhD | Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital
Abstract: 5508

5:36 PM CDT: New Kids on the Block for Ovarian Cancer
Discussant: Christina Fotopoulou, MD, PhD | Imperial College London

5:48 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

ORAL ABSTRACT SESSION: LATE-BREAKING ABSTRACT SESSION: PRESENTATION AND DISCUSSION OF LBA5507

Date: June 4, 2023 |7:30 AM CDT | Location: HALL D1

7:30 AM CDT: Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
Presenter: Kathleen N. Moore, MD, MS | Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Sciences Center
Abstract: LBA5507

GOG PARTNERS

7:42 AM CDT: Discussion of LBA5507
Discussant: Roisin Eilish O'Cearbhaill, MD | Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

7:52 AM CDT: Panel Question and Answer
Chair: Panel Speaker: Panel Discussion | ASCO

EDUCATION SESSION: PARP INHIBITORS: OPTIMAL SELECTION AND TOXICITY MANAGEMENT

Date: June 4, 2023 |8:00 AM CDT | Location: E450

8:00 AM CDT: Living on a PARPi
Speaker: Susan Feinberg | Facing Our Risk of Cancer Empowered

8:15 AM CDT: Real-World Experience in Managing PARP Inhibitor Toxicities
Speaker: Michael Friedlander, MD, PhD | Prince of Wales Hospital

8:30 AM CDT: Updates on the Status on PARP Inhibitors in Ovarian Cancer
Chair: William P. Tew, MD | Memorial Sloan Kettering Cancer Center

8:45 AM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

EDUCATION SESSION: CANCER DURING PREGNANCY: MEDICAL, PSYCHOSOCIAL, ETHICAL, AND LEGAL CONSIDERATIONS

Date: June 4, 2023 |9:45 AM CDT | Location: E451

9:45 AM CDT: A Framework for Patient-centered Care in the Management of Cancer During Pregnancy
Chair: Ann H. Partridge, MPH, FASCO | Dana-Farber Cancer Institute

10:00 AM CDT: Treatment Options and Timing in the Management of Cancer during Pregnancy
Speaker: Alison W. Loren, MD, MSCE | University of Pennsylvania

1**0:15 AM CDT: Obstetric and Neonatal Issues in the Multidisciplinary Management of Cancer during Pregnancy**
Speaker: Frederic Amant, MD | UZ Gasthuisberg - Katholieke University Leuven

10:30 AM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

TICKETED SESSION: MEET THE PROFESSORS: OVERCOMING GEOGRAPHICAL OBSTACLES IN CERVICAL CANCER CARE

Date: June 5, 2023 |9:45 AM CDT | Location: E253d

9:45 AM CDT: Obstacles to Gynecologic Cancer Care in South America
Speaker: Ricardo Dos Reis, PhD | Barretos

10:05 AM CDT: The WHO Cervical Cancer Elimination Initiative: Lessons Learned on Access to Care
Speaker: Patti Gravitt, PhD | National Cancer Institute Sri Lanka

10:25 AM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

Active bone marrow-sparing to reduce the incidence of grade 3+ acute hematologic toxicity in patients with locally advanced cervical cancer who receive chemoradiotherapy: A single-center prospective randomized controlled trial.
Presenter: ShanBing Wang | Department of Oncology, the Second People's Hospital of Yibin City
Abstract: 5524 | Poster Bd #: 219

Neoplastic and blood-based biomarkers of response in patients with advanced endometrial cancer: Results from NRG GY012.
Presenter: Helen Mackay, MD, MRCP | Odette Cancer Centre, Sunnybrook Health Sciences Centre
Abstract: 5525 | Poster Bd #: 220

Molecular tumor profiling and therapy selection in advanced gynecological cancers: A retrospective cohort analysis from the Australian Molecular Screening and Therapeutics (MoST) Program.
Presenter: Damien Kee, MBBS | Austin Health and Peter MacCallum Cancer Centre
Abstract: 5526 | Poster Bd #: 221

Association of HRD ovarian cancer by RAD51 with hot immune microenvironment: Translational analyses of MITO 16A/MaNGO-OV2 trial.
Presenter: Antonino Musolino, MD, PhD, MSc | University of Parma
Abstract: 5527 | Poster Bd #: 222

SHR-1701 in combination with platinum-based chemotherapy and BP102 (a bevacizumab biosimilar) for persistent, recurrent, or metastatic cervical cancer: Data from a phase 1b/3 study.
Presenter: Jihong Liu | Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center
Abstract: 5529 | Poster Bd #: 224

Efficacy and safety of combining PD-1 blockage and human papillomavirus vaccine for patients with relapsed/refractory advanced cervical cancer.
Presenter: Buhai Wang, MD, PhD | Cancer Institute of Northern Jiangsu People's Hospital
Abstract: 5530 | Poster Bd #: 225

The efficacy and safety of tislelizumab plus bevacizumab and chemotherapy as first line therapy in patients with persistent, recurrent, or metastatic cervical cancer: A multicenter, phase II study.
Presenter: Jianqing Zhu, MD | Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)
Abstract: 5531 | Poster Bd #: 226

A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101.
Presenter: Takahide Arimoto, MD, PhD | Toranomon Hospital
Abstract: 5532 | Poster Bd #: 227

Patient-reported outcomes during pelvic radiation therapy: A secondary analysis on sexual function from NRG-RTOG 1203.
Presenter: Kelsey L Corrigan, MD, MPH | Department of Radiation Oncology, University of Texas MD Anderson Cancer Center
Abstract: 5533 | Poster Bd #: 228

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

The value of progression-free survival at three years as a primary endpoint for studies on radiotherapy in patients with locally advanced cervical cancer: Individual patient data from Chinese National Cancer Center and validation from 27 global randomized trials.
Presenter: Xi Yang, MD | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
A**bstract: 5534 | Poster Bd #: 229**

A multicenter, open-label, single-arm, phase II trial to evaluate the efficacy and safety of geptanolimab (GB226) in the treatment of patients (pts) with programmed cell death ligand 1 (PD-L1)–positive recurrent or metastatic cervical cancer, for whom prior platinum-containing chemotherapy has failed.
Presenter: Jusheng An, MD,PHD | National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Abstract: 5535 | Poster Bd #: 230

Final results of a phase II trial of prolgolimab with platinum-based therapy and bevacizumab in patients with advanced cervical cancer.
Presenter: Lyudmila Zhukova, MD, PhD | Moscow Clinical Scientific Center named after A.S. Loginov
Abstract: 5536 | Poster Bd #: 231

Development of cervical cancer patient reported clinical outcome assessment scale (CC-PRO137): A dedicated tool for multidimensional evaluation of treatment outcomes.
Presenter: Xin Wu, MD | Obstetrics and Gynecology Hospital, Fudan University
Abstract: 5537 | Poster Bd #: 232

A peptide-based human papillomavirus therapeutic vaccine, PepCan, or Candida adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
Presenter: Mayumi Nakagawa, MD, PhD | University of Arkansas for Medical Sciences
Abstract: 5538 | Poster Bd #: 233

Surgical resection based on ontogenetic cancer field theory for cervical cancer: 10-year updated results of the MMR study.
Presenter: Laura Weydandt, MD | University of Leipzig Medical Center, Department of Gynecology
Abstract: 5539 | Poster Bd #: 234

Association between serum folate and vitamin B12 and cervical high-risk human papillomavirus (HPV) infection.
Presenter: Josephine Peitz | University of Maryland School of Medicine
Abstract: 5541 | Poster Bd #: 236

Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.
Presenter: Zhongjie Chen | Tianjin Medical University Cancer Hospital & Institute
Abstract: 5542 | Poster Bd #: 237

The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
Presenter: Muhammad Danyal Ahsan | Weill Cornell Medicine - Qatar
Abstract: 5543 | Poster Bd #: 238

POSTER SESSION GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.
Presenter: Nehal J. Lakhani, MD, PhD | START Midwest
Abstract: 5544 | Poster Bd #: 239

Correlating expression of NaPi2b and FRa in high grade serous ovarian cancer (HGSOC).
Presenter: Debra L. Richardson, MD | Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute
Abstract: 5545 | Poster Bd #: 240

Systematic high-throughput combination drug screen to enhance poly (ADP-ribose) polymerase (PARP) inhibitor efficacy in ovarian cancer.
Presenter: Katherine Foster, MD | The University of Texas MD Anderson Cancer Center
Abstract: 5546 | Poster Bd #: 241

The impact of adjuvant platinum-based chemotherapy in early adult granulosa cell tumor of the ovaries: A meta-analysis of comparative studies.
Presenter: Dinesh Keerty, MD, FACP | LSUHSC-S, Feist-Weiller Cancer Center
Abstract: 5547 | Poster Bd #: 242

Nivolumab plus ipilimumab (N+I) in patients (pts) with ovarian cancer (OC) with BRCA1/2 mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Presenter: Charles Drescher, MD | Swedish Cancer Institute
Abstract: 5548 | Poster Bd #: 243

Utility of surgically documented minimal residual disease as a therapeutic target and early surrogate of frontline treatment outcomes in ovarian cancer.
Presenter: Anne Knisely | University of Texas MD Anderson Cancer Center
Abstract: 5549 | Poster Bd #: 244

Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
Presenter: Philipp Harter, MD, PhD | Kliniken Essen-Mitte, and AGO
Abstract: 5550 | Poster Bd #: 245

Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).
Presenter: Yang Shen | Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University
Abstract: 5551 | Poster Bd #: 246

Venous thromboembolism prophylaxis during neoadjuvant chemotherapy for patients with ovarian cancer.
Presenter: Hannah Dysinger McLaughlin, MD | University of Michigan Hospital
Abstract: 5552 | Poster Bd #: 247

Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).
Presenter: Sumitra Ananda, MBBS, FRACP | Peter MacCallum Cancer Centre, Epworth Healthcare, Western Health, Walter and Eliza Hall Institute, University of Melbourne
Abstract: 5553 | Poster Bd #: 248

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

Safety and efficacy of PIPAC in ovarian cancer patients with peritoneal metastases: A first-in-US phase I study.
Presenter: Rosemary Senguttuvan, MD | City of Hope National Medical Center
Abstract: 5554 | Poster Bd #: 249

Analyses of tumor microenvironment affecting the survival in patients with ovarian cancer receiving intraperitoneal chemotherapy: Translational research from the phase 3 trial of intraperitoneal therapy for ovarian cancer with carboplatin (TRiPocc).
Presenter: Aiko Ogasawara, MD, PhD | Aichi Cancer Center Research Institute
Abstract: 5555 | Poster Bd #: 250

Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial.
Presenter: Yuanming Shen, MD | Women's Hospital School of Medicine Zhejiang University
Abstract: 5556 | Poster Bd #: 251

The role of innate immune system in modulating CHK1 inhibitor (CHK1i) response in BRCA wild-type (BRCAwt), platinum-resistant high-grade serous ovarian cancer (PR-HGSOC): Exploratory analysis from a phase II study of CHK1i prexasertib.
Presenter: Elena Giudice, MD | Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health
Abstract: 5557 | Poster Bd #: 252

DNA methylation patterns between tissue and blood samples in ovarian cancer.
Presenter: Hao Wen | Department of Gynecological Oncology, Fudan University Shanghai Cancer Center
Abstract: 5558 | Poster Bd #: 253

BRCA1 and RAD51 methylation impact on outcome in patients with advanced ovarian cancer: A PAOLA-1 ancillary study.
Presenter: Helene Blons | APHP, European Georges Pompidou Hospital, Department of Biochemistry, Pharmacogenetics and Molecular Oncology, Paris Cancer Institute CARPEM
Abstract: 5559 | Poster Bd #: 254

Randomized phase 2 trial of personal dendritic cell (DC)-autologous tumor antigen (ATA) vaccines in newly diagnosed advanced ovary cancer.
Presenter: Bradley Corr, MD | University of Colorado Cancer Center
Abstract: 5560 | Poster Bd #: 255

Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response: A translational sub-study of the REZOLVE (ANZGOG-1101) clinical trial.
Presenter: Bonnita Werner, BSc | UNSW
Abstract: 5561 | Poster Bd #: 256

Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.
Presenter: Beihua Kong, MD | Qilu Hospital of Shandong University
Abstract: 5562 | Poster Bd #: 257

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer.
Presenter: P. B. Ottevanger, MD, PhD | Radboud University Medical Center
Abstract: 5563 | Poster Bd #: 258

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.
Presenter: Sarah Shin, MD, MPH | Developmental Therapeutics Clinic/Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute
Abstract: 5564 | Poster Bd #: 259

Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.
Presenter: Ryan M Kahn, MD | Memorial Sloan Kettering Cancer Center
Abstract: 5565 | Poster Bd #: 260

Anastomotic leakage following bowel resection in radical cytoreductive surgery for ovarian cancer: A subgroup analysis of the prospective AGO-OVAR.OP3/LION.
Presenter: Bastian Czogalla, M.D. | Department of Obstetrics and Gynecology, University Hospital, Ludwig-Maximilians-Universität München
Abstract: 5566 | Poster Bd #: 261

Proactive assessment of patient reported outcomes in patients with ovarian cancer.
Presenter: Ainhoa Madariaga, MD | 12 de Octubre University Hospital
Abstract: 5567 | Poster Bd #: 262

The effect of maintenance hormone therapy on overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
Presenter: Syem Barakzai, MD | Massachusetts General Hospital
Abstract: 5568 | Poster Bd #: 263

CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.
Presenter: Alexandra Leary, MD, PhD | Gustave Roussy Cancer Center, INSERM U981, and Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO)
Abstract: 5569 | Poster Bd #: 264

Trends in ovarian cancer incidence and incidence-based mortality: A 15-year population-based analysis.
Presenter: Sahana Somasegar, MD | Stanford University School of Medicine
Abstract: 5570 | Poster Bd #: 265

Mechanisms of resistance to bispecific T-cell engager therapy for ovarian cancer.
Presenter: Syem Barakzai, MD | Massachusetts General Hospital
Abstract: 5571 | Poster Bd #: 266

Patterns of ovarian cancer care in an elderly population in Australia: A prospective cohort study from the National Gynaecology Oncology Registry (NGOR).
Presenter: Mahendra Naidoo, FRACP, MBChB, MPH | Monash University School of Public Health and Preventive Medicine - Cancer Research Program
Abstract: 5572 | Poster Bd #: 267

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

Impact of cytoreductive surgery on survival outcomes for recurrent adult-type granulosa cell tumors of the ovary.
Presenter: Jeffrey How, MD, MS, MPH | University of Texas MD Anderson Cancer Center
Abstract: 5573 | Poster Bd #: 268

A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
Presenter: Stephanie Gaillard, MD, PhD | Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Abstract: 5574 | Poster Bd #: 269

Anlotinib combined with carboplatin/paclitaxel and maintenance anlotinib as front-line treatment for newly diagnosed advanced ovarian cancer: A phase II, single-arm, multicenter study (ALTER-GO-010).
Presenter: Wenjun Cheng | Jiangsu Province Hospital
Abstract: 5575 | Poster Bd #: 270

Understanding differences in the rates of BRCA/HRD testing and treatment in 1st line maintenance in patients with ovarian cancer treated by gynecologic oncologists compared to other providers: A quality initiative by Integra Connect (IC) PrecisionQ.
Presenter: Fred J. Kudrik, MD | South Carolina Oncology Associates
Abstract: 5576 | Poster Bd #: 271

First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors.
Presenter: Jifang Gong, MD | Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology/Early Drug Development Center, Peking University Cancer Hospital & Institute
Abstract: 5577 | Poster Bd #: 272

Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.
Presenter: Genevieve MacAulay Vacheresse, MD | University of Ottawa
Abstract: 5578 | Poster Bd #: 273

Molecular and immune profiling of TP53-mutated ovarian cancers with non-BRCA1/2 homologous recombination gene alterations.
Presenter: Kyle C Strickland, MD, PhD | Labcorp Oncology | Duke University Medical Center, Duke Cancer Institute, Department of Pathology
Abstract: 5579 | Poster Bd #: 274

Exploring the significance of PARP inhibitor therapy after first-line chemotherapy in patients with homologous recombination proficient ovarian cancer: An extracted individual patient data and trial-level meta-analysis.
Presenter: Mateus Trinconi Cunha, MD | Instituto do Câncer do Estado de São Paulo, University of São Paulo
Abstract: 5580 | Poster Bd #: 275

Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
Presenter: Jason Silberman, MD | Massachusetts General Hospital
Abstract: 5581 | Poster Bd #: 276

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

Distinguishing primary mucinous ovarian tumors from metastases of non-gynecologic mucinous cancers: Can we leverage next-generation sequencing?
Presenter: Muhammad Danyal Ahsan | Weill Cornell Medicine - Qatar
Abstract: 5582 | Poster Bd #: 277

Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.
Presenter: Debra L. Richardson, MD | Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute
Abstract: 5583 | Poster Bd #: 278

Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
Presenter: Yoo Na Kim, MD | Department of Obstetrics and Gynecology, Yonsei University College of Medicine
Abstract: 5584 | Poster Bd #: 279

The diagnostic landscape of HRD testing based on cross-sectional survey of physicians and molecular biologists conducting testing (INDICATOR ONE).
Presenter: Robert L. Coleman, MD, FACOG, FACS, FASCO | Texas Oncology, Texas, US & Sarah Cannon Research Institute (SCRI), Tennessee, US
Abstract: 5585 | Poster Bd #: 280

Immune features of ovarian tumors with a good response to neo-adjuvant chemotherapy in combination with an anti-PD-L1 alone or with an anti-CTLA4: Data from the randomized IneOV trial (a GINECO study).
Presenter: Alexandra Leary, MD, PhD | Gustave-Roussy Cancer Campus, Villejuif, and GINECO
Abstract: 5586 | Poster Bd #: 281

Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups.
Presenter: Kristina Lindemann, MD, PhD | Department of gynecological oncology, Radiumhospital, Oslo University Hospital & Faculty of Medicine, University of Oslo
Abstract: 5587 | Poster Bd #: 282

Blinded-assessment of a solution to evaluate olaparib maintenance treatment efficacy in patients with ovarian cancer from the GINECO/ENGOT PAOLA-1 trial.
Presenter: Adrien Buisson, PharmD | Department of Biopathology, Centre Léon BERARD
Abstract: 5588 | Poster Bd #: 283

Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.
Presenter: Whitney Graybill | Medical University of South Carolina
Abstract: 5589 | Poster Bd #: 284

GOG PARTNERS

Phase 1/1b study of PRGN-3005 autologous UltraCAR-T cells manufactured overnight for infusion next day to advanced stage platinum resistant ovarian cancer patients.
Presenter: John B. Liao, MD, PhD | University of Washington Medical Center
Abstract: 5590 | Poster Bd #: 285

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

The role of Chemotherapy Response Score (CRS) in the decision making process for advanced high grade serous ovarian cancer patients undergoing neoadjuvant chemotherapy.
Presenter: Claudia Marchetti, BA | Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Abstract: 5591 | Poster Bd #: 286

Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer.
Presenter: Robert L. Coleman | US Oncology Research/Sarah Cannon Research Institute and GOG-Foundation
Abstract: 5592 | Poster Bd #: 287

Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.
Presenter: Natalie Danziger, BS | Foundation Medicine, Inc.
Abstract: 5593 | Poster Bd #: 288

Healthcare access dimensions and uterine cancer survival: A National Cancer Database study.
Presenter: Mary Katherine Anastasio, MD | Duke Medical Center
Abstract: 5594 | Poster Bd #: 289

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.
Presenter: Drew W. Rasco, MD | START San Antonio
Abstract: 5595 | Poster Bd #: 290

Pathogenic germline variants in patients with endometrial cancer across diverse ancestries.
Presenter: Ying L Liu, MD, MPH | Gynecologic Medical Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center
Abstract: 5596 | Poster Bd #: 291

The effect of megestrol acetate +/- pterostilbene in endometrial cancer: A prospective, randomized, window-of-opportunity clinical trial.
Presenter: Rosemary Senguttuvan, MD | City of Hope National Comprehensive Cancer Center
Abstract: 5597 | Poster Bd #: 292

Overall survival and subsequent therapy from a phase II study of sintilimab and anlotinib in patients with advanced or recurrent endometrial cancer.
Presenter: Zhen Zeng | Department of Gynecologic Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou 510060, P. R. China
Abstract: 5598 | Poster Bd #: 293

Preliminary results of a phase II trial with sacituzumab govitecan-hziy in patients with recurrent endometrial carcinoma overexpressing Trop-2.
Presenter: Alessandro Santin, MD | Department of Obstetrics, Gynecology, and Reproductive Sciences Yale University School of Medicine
Abstract: 5599 | Poster Bd #: 294

Racial and ethnic disparities in quality of diagnostic evaluation for uterine cancer among Medicare patients.
Presenter: Xiao Xu, PhD | Yale University
Abstract: 5600 | Poster Bd #: 295

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

OATH trial: A phase II clinical trial evaluating the combination of onapristone with anastrozole for women with hormone receptor positive endometrial cancer—Preliminary results.
Presenter: Russell J. Schilder, MD | Thomas Jefferson University Hospital
Abstract: 5601 | Poster Bd #: 296

Correlation of cardiovascular disease with racial disparities in endometrial cancer outcomes.
Presenter: Mitchell Depke, MD | Medical College of Wisconsin
Abstract: 5602 | Poster Bd #: 297

Association of the Duffy-null allele and endometrial cancer characteristics: An effort to explore racial disparity in Black women with endometrial cancer.
Presenter: Emily M Webster, MD | Weill Cornell Medicine
Abstract: 5603 | Poster Bd #: 298

The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).
Presenter: Yoland Catherine Antill, MD | Cabrini Health
Abstract: 5604 | Poster Bd #: 299

Laparoscopic versus open-surgery in FIGO stage II endometrioid endometrium cancers: Is there a prognostic effect?
Presenter: Daniel Uwe Reimer, MD, PhD | Innsbruck Medical University; Department of Obstetrics and Gynecology
Abstract: 5605 | Poster Bd #: 300

Impact of best practice advisory on genetic counseling referral patterns for patients with endometrial cancer.
Presenter: Julia M Nagle, MD | University of Kentucky Medical Center
Abstract: 5606 | Poster Bd #: 301

Impact of surgical weight loss treatments on care burden among obese endometrial cancer survivors.
Presenter: Katia Noyes, PhD, MPH | University at Buffalo School of Public Health and Health Professions
Abstract: 5607 | Poster Bd #: 302

Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study.
Presenter: Yang Shen | Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University
Abstract: 5608 | Poster Bd #: 303

A multicenter, single-arm, phase 2 study of surufatinib plus toripalimab for patients with advanced endometrial cancer.
Presenter: Guangwen Yuan | Cancer Hospital Chinese Academy of Medical Sciences
Abstract: 5609 | Poster Bd #: 304

TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
Presenter: Alessandro Santin, MD | Yale School of Medicine
Abstract: 5610 | Poster Bd #: 305

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

Clinical and genomic landscape of RAS pathway mutations in gynecologic cancers.
Presenter: Ji Son, MD, MS | University of Texas MD Anderson Cancer Center
Abstract: 5611 | Poster Bd #: 306

ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).
Presenter: Thomas J. Herzog, MD | College of Medicine, University of Cincinnati
Abstract: TPS5612 | Poster Bd #: 307a

UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC).
Presenter: John L. Hays, MD, PhD | Wexner Medical Center and The James Cancer Hospital, Ohio State University
Abstract: TPS5613 | Poster Bd #: 307b

UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.
Presenter: Debra L. Richardson, MD | Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute
Abstract: TPS5614 | Poster Bd #: 308a

A randomized trial of olaparib, durvalumab, and cancer vaccine, UV1, as maintenance therapy in patients with BRCAwt with recurrent ovarian cancer: ENGOT-OV56/NSGO-CTU-DOVACC trial.
Presenter: Mansoor Raza Mirza, MD | NSGO-CTU & Rigshospitalet, Copenhagen University Hospital
Abstract: TPS5615 | Poster Bd #: 308b

A phase 1/2 open-label, multicenter, dose escalation and expansion study of AVB-001, an intraperitoneally administered, cell-generated, human IL-2 immunotherapy in patients with platinum-resistant, high-grade, serous adenocarcinoma of the ovary, primary peritoneum, or fallopian tube.
Presenter: Shannon Neville Westin, MD | University of Texas MD Anderson Cancer Center
Abstract: TPS5616 | Poster Bd #: 309a

CRI-CCTG-0003/IND.240: An immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC).
Presenter: Helen Mackay, MD, MRCP | Odette Cancer Centre, Sunnybrook Health Sciences Centre
Abstract: TPS5617 | Poster Bd #: 309b

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.
Presenter: Alexandra Leary, MD, PhD | Gustave-Roussy Cancer Campus, Villejuif, and GINECO
Abstract: TPS5618 | Poster Bd #: 310a

Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.
Presenter: Jeffrey How, MD, MS, MPH | University of Texas MD Anderson Cancer Center
Abstract: TPS5619 | Poster Bd #: 310b

POSTER SESSION GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).
Presenter: Elena Ioana Braicu, MD, PhD | Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum and North-Eastern German Society of Gynaecological Oncology (NOGGO) and Stanford University
Abstract: TPS5620 | Poster Bd #: 311a

Oregovomab and non-platinum chemotherapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients not candidates for platinum retreatment: A multicenter, two-cohort, single-arm phase 2 trial (OPERA/KGOG 3065/APGOT-OV6).
Presenter: JUNG-YUN LEE, MD, PhD | Yonsei University College of Medicine
Abstract: TPS5621 | Poster Bd #: 311b

GOG PARTNERS

GLORIOSA: A randomized, open-label, phase 3 study of mirvetuximab soravtansine with bevacizumab vs. bevacizumab as maintenance in platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
Presenter: David M. O'Malley, MD | James Gynecologic Oncology Mill Run, Ohio State University
Abstract: TPS5622 | Poster Bd #: 312a

GOG PARTNERS

Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.
Presenter: Helen Mackay, MD, MRCP | Odette Cancer Centre, Sunnybrook Health Sciences Centre
Abstract: TPS5623 | Poster Bd #: 312b

First-in-human phase 1/2 study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer.
Presenter: Kathleen N. Moore, MD, MS | Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute
Abstract: TPS5624 | Poster Bd #: 313a

FLORA-5/GOG3035: Chemo-immunotherapy (paclitaxel-carboplatin-oregovomab [PCO] vs chemotherapy (paclitaxel-carboplatin-placebo [PCP]) as front-line treatment in patients with advanced epithelial ovarian cancer (EOC)—Phase III, double blind, placebo controlled, global, multinational study.
Presenter: Lisa Marie Barroilhet, MD, MS | University of Wisconsin
Abstract: TPS5625 | Poster Bd #: 313b

GOG PARTNERS

A phase II, randomized, double-blind study of the use of rucaparib vs placebo maintenance therapy in metastatic and recurrent endometrial cancer.
Presenter: Bradley Corr, MD | University of Colorado Cancer Center
Abstract: TPS5626 | Poster Bd #: 314a

ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.
Presenter: Ignace Vergote, MD, PhD | University Hospitals Leuven, Leuven Cancer Institute, and BGOG
Abstract: TPS5627 | Poster Bd #: 314b

GOG PARTNERS

POSTER SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |1:15 PM CDT | Location: Hall A

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair–proficient (MMR-P) recurrent or persistent endometrial cancer (EC).
Presenter: Elizabeth Katherine Lee, MD | Medical Oncology, Dana-Farber Cancer Institute
Abstract: TPS5628 | Poster Bd #: 315a

A randomized phase II study comparing single-agent olaparib, single-agent cediranib, and the combinations of cediranib/olaparib, olaparib/durvalumab (MEDI4736), cediranib/durvalumab (MEDI4736), and olaparib/AZD5363 (capivasertib) in women with recurrent, persistent, or metastatic endometrial cancer.
Presenter: BJ Rimel, MD | Cedars-Sinai Medical Center
Abstract: TPS5629 | Poster Bd #: 315b

Randomized phase III trial in MMR deficient (MMRd) endometrial cancer (EC) patients comparing chemotherapy (CT) alone versus dostarlimab in first line advanced/metastatic setting: DOMENICA study (GINECO-EN105b/ENGOT-en13 study).
Presenter: Florence Joly, MD, PhD | Centre François Baclesse, Caen and GINECO
Abstract: TPS5630 | Poster Bd #: 316a

RT-PACE: Phase I/II study of adjuvant whole pelvic hypofractionated radiotherapy for non-metastatic cervical and endometrial cancer.
Presenter: Christina H. Son, MD | University of Chicago
Abstract: TPS5631 | Poster Bd #: 316b

CCTG EN10: A phase II study of tailored adjuvant therapy in POLE-mutated and p53-wildtype/NSMP early-stage endometrial cancer (EC)—RAINBO BLUE and TAPER.
Presenter: Jessica N. McAlpine, MD | BCCA, Vancouver Cancer Centre
Abstract: TPS5632 | Poster Bd #: 317a

The RAINBO MMRd-GREEN trial (GCIG/DGOG/ENGOT-EN142): A phase III trial on the addition of adjuvant durvalumab to radiotherapy in patients with high-risk MMRd endometrial cancer.
Presenter: Merve Kaya, MD | Leiden University Medical Center
Abstract: TPS5633 | Poster Bd #: 317b

AFT-50 EndoMAP: A phase IB/II multi-cohort study of targeted agents for patients with recurrent or persistent endometrial cancer.
Presenter: Evelyn Cantillo, MD, MPH | 525 East 68th St
Abstract: TPS5634 | Poster Bd #: 318a

GCIG SB-001/NSGO-CTU-PEACE/ANZGOG 1923/2020: Palliation in gynae-oncology—Patients' expectations and assessment of care.
Presenter: Kristina Lindemann, MD, PhD | NSGO-CTU, Denmark & Dep. of Gynaecologic Oncology, Oslo University Hospital & Faculty of Medicine, University of Oslo
Abstract: TPS5635 | Poster Bd #: 318b

POSTER DISCUSSION SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |4:30 PM CDT | Location: S100bc

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.
Presenter: Panagiotis A. Konstantinopoulos, MD | Dana-Farber Cancer Institute
Abstract: 5512 | Poster Bd #: 207

Correlation of cyclin E1 expression and clinical outcomes in a phase 1b dose-escalation study of azenosertib (ZN-c3), a WEE1 inhibitor, in combination with chemotherapy (CT) in patients (pts) with platinum-resistant or refractory (R/R) epithelial ovarian, peritoneal, or fallopian tube cancer (EOC).
Presenter: Joyce F. Liu, MD | Department of Medical Oncology, Dana-Farber Cancer Institute
Abstract: 5513 | Poster Bd #: 208

A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.
Presenter: Andreia Cristina De Melo, MD | Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Brazilian Gynecologic Oncology Group (EVA), Brazil; Division of Clinical Research and Technological Development - Brazilian National Cancer Institute (INCA)
Abstract: 5514 | Poster Bd #: 209

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).
Presenter: Susana N. Banerjee, PhD, FRCP, MA, MBBS | The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, National Cancer Research Institute (NCRI)
Abstract: 5515 | Poster Bd #: 210

GOG PARTNERS

4:30 PM CDT: Meeting at the TKI Bar
Discussant: Jalid Sehouli, MD | Charité University of Medicine Virchow Campus Clinic

4:42 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

**A phase II basket trial of dual anti–CTLA-4 and anti–PD-1 blo
ckade in rare tumors (DART) SWOG S1609: The vulvar cancers.**
Presenter: Young Kwang Chae, MD, MBA | Northwestern University
Abstract: 5517 | Poster Bd #: 211

4:52 PM CDT: Expanding Options in Immunotherapy for Gynecologic Cancers
Discussant: Oliver Dorigo, MD, PhD | Stanford Medicine

5:04 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018.
Presenter: Kazuto Nakamura, MD, PhD | Department of Gynecology, Gunma Prefectural Cancer Center
Abstract: 5519 | Poster Bd #: 213

POSTER DISCUSSION SESSION: GYNECOLOGIC CANCER

Date: June 5, 2023 |4:30 PM CDT | Location: S100bc

Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial.
Presenter: Chaoyang Sun | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Abstract: 5520 | Poster Bd #: 214

Advanced cervical cancer therapy: Comparison of contemporary expert and healthcare professional recommendations from an online treatment decision tool.
Presenter: Jerfiz Constanzo, PhD, MBA | Clinical Care Options
Abstract: 5528 | Poster Bd #: 215

5:14 PM CDT: Optimizing Treatment for Cervical Cancer
Discussant: Jennifer Michelle Scalici, MD | University of South Alabama Mitchell Cancer Institute

5:26 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO

Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.
Presenter: Florence Joly, MD, PhD | Department of Medical Oncology, Centre François Baclesse
Abstract: 5521 | Poster Bd #: 216

The Normal Risk Ovarian Screening Study (NROSS): Twenty-one year update.
Presenter: Chae Young Han, Ph.D | The UT MD Anderson Cancer Center
Abstract: 5522 | Poster Bd #: 217

The effects of the Covid-19 pandemic on practice patterns and outcomes in patients diagnosed with gynecologic malignancies in the United States.
Presenter: Adrian Kohut, MD | City of Hope National Comprehensive Cancer Center
Abstract: 5523 | Poster Bd #: 218

5:36 PM CDT: Everything, Everywhere, All At Once: Treatment Options in Gynecologic Cancer
Discussant: Kathryn Pennington, MD | University of Washington School of Medicine

5:48 PM CDT: Panel Question and Answer
Panel Speaker: Panel Discussion | ASCO